

# Genetic, lifestyle and environmental risk factors for chronic pain revealed through GWAS

Mischa Lundberg<sup>1,2\*</sup>, Adrian I. Campos<sup>3,4</sup>, Scott F. Farrell<sup>5,6</sup>, Geng Wang<sup>1</sup>, Michele Sterling<sup>5,6</sup>, Miguel E. Renteria<sup>4</sup>, Trung Thanh Ngo<sup>1</sup>, Gabriel Cuellar-Partida<sup>1\*</sup>

1. The University of Queensland Diamantina Institute, The University of Queensland, Woolloongabba, QLD 4102, Australia
2. Transformational Bioinformatics, Commonwealth Scientific and Industrial Research Organisation, Sydney, New South Wales, Australia
3. The University of Queensland Faculty of Medicine, Brisbane, Queensland Australia
4. Department of Genetics and Computational Biology, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia
5. RECOVER Injury Research Centre, The University of Queensland Brisbane, Queensland, Australia
6. NHMRC Centre of Research Excellence in Road Traffic Injury Recovery, The University of Qld

\* Correspondence should be addressed to  
 Gabriel Cuellar Partida ([g.cuellarpartida@uq.edu.au](mailto:g.cuellarpartida@uq.edu.au))  
 Mischa Lundberg ([m.lundberg@uq.net.au](mailto:m.lundberg@uq.net.au))

## Abstract

Chronic pain (CP) is a leading cause of disability worldwide with complex aetiologies that remain elusive. Here we addressed this issue by performing a GWAS on a large UK Biobank sample (N=188,352 cases & N=69,627 controls) which identified two independent loci associated with CP near *ADAMTS6* and *LEMD2*. Gene-based tests revealed additional CP-associated genes (*DCAKD*, *NMT1*, *MLN*, *IP6K3*). Across 1328 complex traits, 548 (41%) were genetically correlated with CP, of which 175 (13%) showed genetic causal relationships using the latent causal variable approach and Mendelian randomization. In particular, major depressive disorder, anxiety, smoking, body fat & BMI were found to increase the risk of CP, whereas diet, walking for pleasure & higher educational attainment were associated with a reduced risk (i.e., protective effect). This data-driven hypothesis-free approach has uncovered several specific risk factors that warrant further examination in longitudinal trials to help deliver effective early screening & management strategies for CP.

## Introduction

Chronic pain (CP) is a leading cause of disability affecting around 30%–50% of the world’s population with enormous costs to society [6,23,26,34,49,68,77,86]. CP is typically defined as pain that persists or recurs for more than three months and is considered a clinical entity in its own right [65,71,81]. Although CP often arises as a result of injury or disease, not everyone who is injured will develop the condition. This observation suggests that variation in and interactions between individuals’ environments, lifestyles and genetic makeup play a critical yet elusive role in the aetiology of CP.

Epidemiological studies of CP have identified a myriad of risk factors such as sex and age (demographics), diet and alcohol consumption (lifestyle), and clinical comorbidities (e.g., psychiatric and chronic cardiometabolic conditions) [54]. Evidence for the role of genetic factors in CP comes from twin and family studies [38] where its heritability is estimated to be as high as 60% [11,37]. More recently, large-scale genome-wide association studies (GWAS) have identified multiple genetic variants associated with chronic back pain [25,75] and multisite chronic pain [36] as further evidence of a genetic contribution to CP. However, their causal relationship has yet to be adequately examined. Given the complex multifactorial nature of CP, determining its aetiology in large population samples would not be feasible through conventional experimental methodologies.

In this study, we investigated the genetic aetiology of CP by conducting a GWAS using UK Biobank data [57]. We then used these results in a comprehensive set of downstream analyses to draw insights into the environmental, lifestyle and clinical factors linked to CP. These analyses included estimating the genetic correlation of CP with > 1,300 complex traits and conditions, followed by an assessment of whether the genetic correlations could be explained by a causal relationship through applying Mendelian randomization [90] and latent causal variable analysis [59].

## Methods

### Sample selection

Data for CP was obtained from UK Biobank participant responses to the questions: “Have you had back pains for more than 3 months?”, “Have you had hip pains for more than 3 months?”, “Have you had knee pains for more than 3 months?” , “Have you had neck or shoulder pains for more than 3 months?” , “Have you had abdominal pains for more than 3 months?” , “Have you had facial pains for more than 3 months?” , “Have you had headaches for more than 3 months?” , “Have you had pains all over the body for more than 3 months?” (Questionnaire field ID: 6159) [57]. Each of these

questions could be answered with “Yes”, “No”, “Don’t know”, or “Prefer not to answer”. Individuals that selected “Yes” to any of the questions were defined as cases while those that selected “No” to all the questions were used as controls. The count of individuals included in the analysis reporting pain for more than 3 months and in which body site is shown Table 1. In total, 188,352 (73%) individuals that reported pain at any site for over 3 months (cases) while 69,627 reported not experiencing any pain for over 3 months (controls) were included in the analysis. Informed consent was provided by all participants. The research was approved by the UK Biobank's governing Research Ethics Committee.

## Genome-wide association study

Association testing between CP and genetic variants was conducted using a linear mixed model implemented in Bolt-LMM (v. 2.3.4) [47]. Quality control included exclusion of variants with minor allele frequency (MAF) < 0.005, imputation quality < 0.6 and those deviating from Hardy–Weinberg equilibrium (P-value <  $1 \times 10^{-5}$ ). Subject data were excluded if their genotype-derived principal components 1 and 2 were further than 6 standard deviations away from those of 1000 Genomes European population. Sex, age and the top 20 principal components derived from genetic data were used as covariates for the association analysis. In addition, a sex-stratified GWA analysis of CP was performed using the same parameters but without sex as a covariate.

## Post-GWAS analyses

Post-GWAS analyses were performed on the Complex Traits Genetics Virtual Lab (CTG-VL) [18] — a freely available web platform for running commonly used statistical genetics analysis methods alongside GWAS summary-level statistics of 1,328 traits & diseases. As described further below, these downstream analyses used summary statistics from the CP GWAS to carry out gene-based and gene-set enrichment analyses, genetic correlation estimates and assess their causal relationship.

## Gene-based & gene-set enrichment analyses

Gene-based association analysis was carried out using the fastBAT [3] implemented in CTG-VL [18]. fastBAT estimates the overall association of SNPs within a 50kb from each gene using GWAS summary statistics and reference genotypes from the 1000 Genomes project European population to account for linkage-disequilibrium between the SNPs. Through this method, we tested the association of 24,254 genes with CP. The Bonferroni’s corrected P-value level of significance was  $2.05 \times 10^{-6}$ .

Gene-set enrichment analyses were performed using DEPICT [63] (v. 1 rel. 194) which is able to identify pathways and tissues/cell types that are most likely to underlie GWAS associations. Briefly, DEPICT assesses whether genes in associated loci are highly expressed in any of the 209 Medical Subject Heading (MeSH) tissue and cell type annotations based on RNA-seq data from the GTEx project [78]. Further, it assesses whether there is an enrichment of genes identified in particular molecular pathways constructed based on 14,461 gene sets from diverse databases [63]. As input for DEPICT, we used independent SNPs (based on clumping with an  $r^2$  (LD) between SNPs < 0.05 and 1Mb windows) with a P-value <  $1 \times 10^{-5}$ .

### Heritability, Genetic correlations & causality analyses

Genome-wide SNP Heritability ( $h_g^2$ ) was calculated using LDSC. We transformed the  $h^2$  estimate from observed to liability scale using prevalence estimates of our sample (73%) and a population prevalence of 50 % [12,23,30,51,53,75,85,86,91,92] using the commands `--samp-prev 0.73` and `--pop-prev 0.5`. The liability scale heritability ( $h_{SNP}^2$ ) corrects for ascertainment bias regarding the prevalence of the condition.

We estimated pair-wise genome-wide genetic correlation ( $r_g$ ) between CP and 1,328 phenotypes using Linkage Disequilibrium Score Regression (LDSC) [9,10] implemented in CTG-VL [18]. To assess whether statistically significant (FDR < 5%) genetic correlations observed could be due to a causal relationship between traits, we then applied the Latent Causal Variable (LCV) method [59]. Briefly, LCV estimates the genetic causal proportion (GCP) whose absolute value ranges from 0 (no partial genetic causality) to 1 (full genetic causality). A high GCP value indicates that trait one is likely to affect trait two. A negative value indicates that trait two affects trait one. In our study CP was set as trait 1, meaning that a positive GCP suggest that CP affects the tested trait while a negative GCP indicates that CP is affected by the tested trait.

Generalized Summary-data-based Mendelian Randomization (GSMR) [90] implemented in gcta (v. 1.92.4beta) was used in addition to the LCV method to assess for potential causal relationships. For this, we used GWAS summary statistics for those traits displaying significant genetic correlations and that had a least three independent instrumental variables (i.e. SNPs with an association P-value <  $5 \times 10^{-8}$  with the exposure). Furthermore, given that two-sample MR may be biased due to weak instruments when both, the exposure and the outcome GWAS are drawn from the same sample, as a sensitivity analysis, we leveraged the sex-stratified GWAS of CP and the sex-stratified GWAS summary statistics from Neale lab [57] [<http://www.nealelab.is/uk-biobank>] to perform GSMR

analysis using GWAS summary statistics of CP in males and GWAS summary statistics of exposures in females and vice versa, thus ensuring non-overlapping samples.

## Results

### Genome-wide association of chronic pain

After quality control (Methods), our GWAS included 188,352 (73%) CP cases (individuals that reported pain at any site for over 3 months) and 69,627 controls. No evidence for inflated statistics due to hidden population stratification was detected (the LDSC intercept estimate was  $1.002 \pm 0.008$ ). The SNP heritability of CP on the liability scale was  $h^2_{SNP}$  (s.e.) = 6.2% (0.51%). Two loci were identified at genome-wide levels of significance (P-value  $< 5 \times 10^{-8}$ ) (Figure 1 and Table 2). The lead SNPs at these loci were rs10660361 and rs113313884 which are located in the intronic region of *LEMD2* in chromosome 5 and *ADAMTS6* in chromosome 6 respectively (Figure 1b and 1c). Using Complex Traits Genetics Virtual Lab (CTG-VL) [18], we explored whether those SNPs have been previously associated to other traits. We observed that rs10660361 was also identified by a recent GWAS on back pain (P-value =  $7.77 \times 10^{-8}$ ) [25] and multisite chronic pain (P-value =  $1.9 \times 10^{-9}$ ) [36]. However, rs113313884 was only associated with multisite chronic pain at a suggestive level (P-value =  $6.9 \times 10^{-3}$ ) highlighting the importance of studying phenotypes using different definitions. We observed that these SNPs are also associated to anthropometric traits including height, BMI, and body fat percentage. Furthermore, rs10660361 is strongly associated to platelet count (P-value =  $4.19 \times 10^{-60}$ ). Results for all significant and suggestive associations are included in Supplementary Table 1.

Epidemiological studies have established a difference in prevalence of CP between sexes (~60% females and ~40% males by age 50) [1,4,8,21,61,64,72,73]. In line with this, data from UK Biobank showed a prevalence of 56.76% in females and 43.24% in males. Here, we sought to explore whether this difference in prevalence may be partly due to genetic differences (e.g. genes involved in hormone regulation may play a role in CP) by performing a sex-stratified GWAS of CP. There were no loci associated with CP in the sex-stratified GWAS at genome-wide levels of significance (P-value  $< 5 \times 10^{-8}$ ). Nevertheless, the association of *LEMD2* (rs10660361) and *ADAMTS6* (rs113313884) with CP was still suggestive in both, males (P-value =  $1.9 \times 10^{-7}$ , Beta (s.e.) =  $1.1 \times 10^{-2}$  ( $2.0 \times 10^{-3}$ ) and P-value =  $5.1 \times 10^{-5}$ , Beta (s.e.) =  $2.4 \times 10^{-2}$  ( $5.8 \times 10^{-3}$ )) and females (P-value =  $1.3 \times 10^{-3}$ , Beta (s.e.) =  $5.5 \times 10^{-3}$  ( $1.7 \times 10^{-3}$ ) and P-value =  $2.8 \times 10^{-5}$ , Beta (s.e.) =  $2.0 \times 10^{-2}$  ( $4.9 \times 10^{-3}$ )). The genetic correlation derived from a bivariate *Linkage Disequilibrium Score Regression* (LDSC) [10] analysis between GWAS of CP in

males and CP in females suggested that CP in males and females is influenced by the same genetic factors  $r_G$  (s.e.) = 1.0 (0.1022).

## Gene-based, pathway and tissue enrichment analyses of chronic pain

The gene-based association analysis revealed five significant ( $P$ -value  $< 2.06 \times 10^{-6}$ ) genes associated with CP (Table 2). The association of three of the genes (*LEMD2*, *MLN*, and *IP6K3*) was driven by the lead SNP rs10660361 identified in the GWAS. However, *DCAKD* and *NMT1* were in the 17q21.31 locus that was not identified during the main GWAS. Full results of the *fast and flexible gene- or set-Based Association Test* (fastBAT) [3] analysis are shown in Supplementary Table 2. Pathway and tissue enrichment analyses performed using DEPICT [63] did not identify any pathways or tissues associated with CP (false discovery rate  $< 5\%$ ). The full results for pathway and tissue enrichment analyses are shown in Supplementary Table 3 and 4.

## Genetic correlations and causality assessment

Bivariate LDSC analyses [9,10] between CP and 1,328 traits revealed 548 genetically correlated traits at Benjamini-Hochberg's *false discovery rate* (FDR)  $< 5\%$  (Supplementary Table 5). As expected, the largest positive genetic correlations were observed for pain-related traits in addition to musculoskeletal conditions. We also observed positive genetic correlation with sleep disorders, including sleep apnoea and psychiatric traits and disorders including anxiety, attention deficit and hyperactivity disorder (ADHD) as well as depression. Current smoking had also a positive genetic correlation with CP while alcohol intake variables such as being a current alcohol consumer or whether alcohol is taken during meals was negatively correlated with CP.

To assess whether the observed genetic correlations observed were due to pleiotropy or a causal relationship, we used the *Latent Causal Variable* (LCV) approach [59] to estimate the *genetic causal proportion* (GCP) on the 548 traits displaying genetic correlations at FDR  $< 5\%$ . The causal architecture plot [29] summarizes the LCV results is shown in Figure 2. Supplementary Table 5 shows the complete results for these analyses. Briefly, traits displaying a negative GCP suggest that they may cause CP, while traits with a positive GCP suggest that the trait may be caused by CP. Furthermore, the sign of the genetic correlation coefficient indicates whether the causal trait decreases or increases the risk of CP. In total, we identified 84 potential causal relationships at FDR  $< 5\%$  using the LCV method, most of them (83/84) affecting CP rather than CP having an impact on them. Among traits with evidence of a causal relationship, we found that dietary behaviours such as consumption of cereal, starch and tea were associated with a reduced risk of CP while vitamin supplementation was associated with an increased risk of CP. These results may arise due to

underlying conditions that lead to the intake of vitamins and CP. As expected, we observed that fibromyalgia related traits and musculoskeletal conditions including arthritis and spondylitis had the strongest evidence of causally increasing the risk of CP. Furthermore, we found that endocrine, nutritional and metabolic diseases including having high cholesterol may increase the risk of CP. Finally, there was some evidence of major depressive disorder and sleep disorders increasing risk of CP. Nevertheless, both associations were below the FDR threshold.

To complement the LCV analysis, we conducted Mendelian randomization using the Generalized Summary-based Mendelian Randomization (GSMR) [90] approach for all the traits displaying genetic correlations. Using GSMR, we were unable to assess if CP affected any trait, as there were insufficient instrumental variables to proxy CP. However, we could identify multiple factors affecting CP. This included evidence of higher body mass index (BMI), whole-body fat mass, waist hip ratio, among other body composition traits to increase the risk of CP. Diseases of the musculoskeletal system and connective tissue including arthrosis displayed an increase of risk of CP. Finally, we also found evidence of educational attainment reducing the risk of CP and Major Depressive Disorder (MDD), mood swings, ADHD, anxiety and smoking increasing the risk of CP.

Given that GSMR can be susceptible to bias (e.g. weak instrument bias) when the exposure and the outcome (CP) GWAS are drawn from the same samples, we leveraged the sex-stratified CP GWAS results, in addition as sex-stratified GWAS summary data from Neale's Lab (see Methods section) [83]. Briefly, we used GWAS performed using only female samples as exposure and GWAS estimated using male samples as outcome (CP) and vice versa. Consequently, we were able to confirm that an increase in BMI, body fat and waist-hip ratio as well as major depressive disorder and anxiety increase the risk of CP while education reduces risk. All results are shown in Supplementary Table 5.

## Discussion

Here we present one of the largest GWAS of CP. We leveraged summary-based data to identify factors that may increase or reduce risk of CP, including genetic, lifestyle and clinical. We discovered variants near *ADAMTS6* and *LEMD2* associated with CP during our main GWAS analysis. *ADAMTS6* has been reported to show increased levels of expression in patients with osteoarthritis [69,76,88] and is associated with heel bone mineral density, which is used in diagnosis of osteoporosis [40,55]. The SNP rs10660361 was closest to *LEMD2*, a gene implicated in embryonic development and the regulation of several signalling pathways [46]. However, we note that this locus was reported in a previous GWAS on multisite chronic pain mapping to the gene *MLN* [36]. It is important to note that

we were unable to map the genes likely affected by these SNPs through more robust approaches (rather than only based on proximity) such as eQTLs. Our tissue enrichment analysis was unable to identify putative cells/tissues of interest where we could look for potential eQTLs. A lookup in the GTEx eQTL database [78] only show suggestive evidence of rs113313884 being associated to the expression of *TRAPPC13* in tibial arteries.

Our gene-based analysis implicated the 17q21.31 locus, particularly the genes *DCAKD* and *NMT1* to be associated with CP. This locus also harbours an inversion polymorphism that has been implicated in numerous neurodegenerative diseases and cognition [80]. *DCAKD* has previously been associated to psychiatric disorders including schizophrenia and bipolar disorder [67]. These results suggest that the association of CP with psychiatric disorders may be partially driven by genetic variation at this locus. Furthermore, *DCAKD* has also been associated with osteoarthritis which is also a potential cause of pain [39]. *NMT1* was already reported to be associated to multisite chronic pain [36], in addition to pulse pressure and insomnia [27,36]. Besides *DCAKD* and *NMT1*, the fastBAT gene-based test also revealed significant associations with *MLN* and *IP6K3*. Both, *MLN* and *IP6K3* are mapped to rs10660361. Polymorphic variations of *IP6K3* contribute to the susceptibility of late onset Alzheimer's disease [17] and BMI [87]. Different variants in *MLN* (*Motilin*) are known for a variety of effects including BMI [15] or depressive symptoms [5]. Further efforts could leverage these results to assess *in vitro* and *in vivo* whether any of these genes is causal for CP, thus identifying potential new therapeutic targets.

The genetic correlation between CP in males and CP in females was not different from the unity ( $r_G = 1.0$ ), suggesting that male and female patients are largely exposed to the same genetic influences and that differences in prevalence may be due to differences in exposure to environmental and lifestyle factors such as smoking, and physical activity amongst others [16,28,41,43]. We identified genetic correlations between CP and a vast array of complex traits ranging from anthropometric to behavioural as well as complex diseases including musculoskeletal and neuropsychiatric disorders. Given that pain is a symptom of many diseases, we carried out a thorough analysis to explore if the genetic correlations were due to horizontal pleiotropy (i.e. the effect of genes on CP is independent from their effect on other traits) or due to a causal relationship.

In line with a recent GWAS on multisite chronic pain [36] and other studies [58,82], we found that depression (including major depressive disorder) and anxiety may increase the risk of CP. This finding is important as so far, studies have been conflicting with regard to whether depression increase the risk of pain or vice versa [13,24,32,35,70,82]. As reported by some epidemiological studies [31,33,48,56,62,74,84] we also observed that increased body fat, BMI and obesity may lead to an



increase in the risk of CP. It is hypothesized that the relationship between obesity and pain may be due dysregulation of inflammatory markers due to inflammatory responses [22,52,60]. We also found that traits describing dietary behaviours such as “Starch” consumption appeared to lead to a decreased risk of CP. This was surprising as starch consumption can increase inflammation [19,42,45,50,89]. “Breakfast cereal consumed” also appeared to have a protective effect on CP. It has been documented that dietary cereal fibre lowers risk of osteoarthritis, which is the most common form of arthritis and a leading cause of chronic pain [20]. In addition to dietary fibre, whole grain cereals contain bioactive components including polyphenols, and flavonoids that have anti-inflammatory properties [2,7]. The identified effect of vitamins increasing the risk for CP might be explained by an indirect causal effect. Briefly, an unobserved trait (such as a disease) that increases the likelihood of both vitamin intake and CP could create an apparent causal effect between vitamin supplementation and increased CP, which is confounded by the unobserved trait. In line with this hypothesis, we also observed variables related to medication usage to increase the risk on CP. For example, the trait “Treatment/medication code: dihydrocodeine” (an opioid analgesic) was associated with an increase of risk for CP. While this might be explained by observations linking opioid intake to increased sensitivity of pain [14,44,66,79], it is possible that taking dihydrocodeine can proxy a pain-causing condition.

Our LCV analyses indicated that CP might be a downstream consequence of multiple traits and diseases and is likely not a cause for other conditions. We identified only one trait that might be causally affected by CP. Unfortunately, we were limited to confirm this pattern through Mendelian randomization as our GWAS of CP did not have enough statistical power and genetic instruments to carry out a bidirectional Mendelian randomization analysis, and thus assess the impact of CP on other traits. Another important limitation is that although we found evidence of effects and their direction of several traits and diseases on CP, it is hard to interpret the magnitude of these effects. The genetic causal proportion estimated through the LCV approach only indicates the proportion of genetic correlation that may be explained through a causal relationship, and thus, it does not produce an odds ratio or effect size estimate. The effect estimates of our Mendelian randomization analyses are similarly hard to interpret as GWAS for CP and the majority of diseases tested have been derived through a linear-mixed model, not a logistic regression and thus working out precise effect estimates is challenging.

In conclusion, we have carried out one of the largest and most extensive studies on CP. We highlight three loci that play a role in the risk of developing CP. Identified no evidence of sex-specific genetic effects and provide evidence of a potential causal role for dozens of traits in the development of CP. Our results call for future studies to assess the roles of ADAMTS6, LEMD2, DCAKD, MLN, NMT1, and

IP6K3 on CP in vitro and in vivo. We furthermore postulate potential modifiable lifestyle factors related to CP which need to be thoroughly assessed and replicated.

## Acknowledgements

This research was conducted using data from the UK Biobank resource (application number 25331). ML, AIC and GW are supported by a University of Queensland Research Training Scholarship from The University of Queensland (UQ). ML thanks the support of the Commonwealth Scientific and Industrial Research Organisation through a Postgraduate Top-Up Scholarship. MER thanks the support of the NHMRC and Australian Research Council (ARC), through a NHMRC - ARC Dementia Research Development Fellowship (GNT1102821). GC-P is funded by an ARC Discovery Early Career Researcher Award (DE180100976). We thank the members of the Evans Lab and Patricia Gerdes for helpful contributions and discussion. RECOVER Injury Research Centre receives unrestricted grant funding from the Motor Accident Insurance Commission (Queensland). The funders had no role in the design or interpretation of this study.

This research was carried out at the Translational Research Institute, Woolloongabba, QLD 4102, Australia. The Translational Research Institute is supported by a grant from the Australian Government.

## Author contributions

GC-P, TTN and MER conceived and directed the study. AIC and MER performed the GWAS. ML performed downstream statistical and bioinformatics analyses, with support from GC-P. GW, SF, MS and TTN acted as advised in the analyses and/or interpretation of results. ML generated all figures and tables. ML and GC-P wrote the manuscript with feedback from all co-authors.

## Competing interests

GC-P. contributed to this study while employed by the University of Queensland but is now an employee of 23andMe Inc. All other authors declare no competing financial interests.

## References

- [1] Aloisi A, Bachiocco V, Costantino A, Stefani R, Ceccarelli I, Bertaccini A, Meriggiola M. Cross-sex hormone administration changes pain in transsexual women and men. *Pain* 2007;132. doi:10.1016/j.pain.2007.02.006.
- [2] Awika JM, Rose DJ, Simsek S. Complementary effects of cereal and pulse polyphenols and dietary fiber on chronic inflammation and gut health. *Food Funct* 2018;9:1389–1409.
- [3] Bakshi A, Zhu Z, Vinkhuyzen AAE, Hill WD, McRae AF, Visscher PM, Yang J. Fast set-based association analysis using summary data from GWAS identifies novel gene loci for human complex traits. *Sci Rep* 2016;6. doi:10.1038/srep32894.
- [4] Bartley EJ, Fillingim RB. Sex differences in pain: a brief review of clinical and experimental findings. *Br J Anaesth* 2013;111:52–58.
- [5] Baselmans BML, Jansen R, Ip HF, Dongen J van, Abdellaoui A, Weijer MP van de, Bao Y, Smart M, Kumari M, Willemsen G, Hottenga J-J, Boomsma DI, Geus EJC de, Nivard MG, Bartels M. Multivariate genome-wide analyses of the well-being spectrum. *Nat Genet* 2019;51:445–451.
- [6] Blyth FM, Briggs AM, Schneider CH, Hoy DG, March LM. The Global Burden of Musculoskeletal Pain—Where to From Here? *Am J Public Health* 2019;109:35–40.
- [7] Bordoni A, Danesi F, Dardevet D, Dupont D, Fernandez AS, Gille D, Santos CN dos, Pinto P, Re R, Rémond D, Shahar DR, Vergères G. Dairy products and inflammation: A review of the clinical evidence. *Critical Reviews in Food Science and Nutrition* 2017;57:2497–2525.
- [8] Breivik H, Collett B, Ventafridda V, Cohen R, Gallacher D. Survey of chronic pain in Europe: Prevalence, impact on daily life, and treatment. *European Journal of Pain* 2006;10:287–287.
- [9] Bulik-Sullivan B, Finucane HK, Anttila V, Gusev A, Day FR, Loh P-R, Duncan L, Perry JRB, Patterson N, Robinson EB, Daly MJ, Price AL, Neale BM. An Atlas of Genetic Correlations across Human Diseases and Traits. *Nat Genet* 2015;47:1236–1241.
- [10] Bulik-Sullivan BK, Loh P-R, Finucane HK, Ripke S, Yang J, Patterson N, Daly MJ, Price AL, Neale BM. LD Score regression distinguishes confounding from polygenicity in genome-wide association studies. *Nature Genetics* 2015;47:291–295.
- [11] Burri A, Ogata S, Rice D, Williams FMK. Twelve-year follow-up of chronic pain in twins: Changes in environmental and genetic influence over time. *Eur J Pain* 2018.
- [12] Burri A, Ogata S, Vehof J, Williams F. Chronic widespread pain: clinical comorbidities and psychological correlates. *Pain* 2015;156:1458–1464.
- [13] Choi KW, Chen C-Y, Stein MB, Klimentidis YC, Wang M-J, Koenen KC, Smoller JW. Assessment of Bidirectional Relationships Between Physical Activity and Depression Among Adults: A 2-Sample Mendelian Randomization Study. *JAMA Psychiatry* 2019;76:399–408.
- [14] Colvin LA, Bull F, Hales TG. Perioperative opioid analgesia—when is enough too much? A review of opioid-induced tolerance and hyperalgesia. *The Lancet* 2019;393:1558–1568.
- [15] Cotsapas C, Speliotes EK, Hatoum IJ, Greenawalt DM, Dobrin R, Lum PY, Suver C, Chudin E, Kemp D, Reitman M, Voight BF, Neale BM, Schadt EE, Hirschhorn JN, Kaplan LM, Daly MJ.

Common body mass index-associated variants confer risk of extreme obesity. *Hum Mol Genet* 2009;18:3502–3507.

- [16] Creed F. A review of the incidence and risk factors for fibromyalgia and chronic widespread pain in population-based studies. *PAIN* 2020;Articles in Press.  
doi:10.1097/j.pain.0000000000001819.
- [17] Crocco P, Saiardi A, Wilson MS, Maletta R, Bruni AC, Passarino G, Rose G. Contribution of polymorphic variation of inositol hexakisphosphate kinase 3 (IP6K3) gene promoter to the susceptibility to late onset Alzheimer's disease. *Biochim Biophys Acta* 2016;1862:1766–1773.
- [18] Cuellar-Partida G, Lundberg M, Kho PF, D'Urso S, Gutierrez-Mondragon LF, Hwang L-D. Complex-Traits Genetics Virtual Lab: A community-driven web platform for post-GWAS analyses. *bioRxiv* 2019:518027.
- [19] Dai Z, Felson DT. Chapter 12 - Prebiotic Fibers and Their Potential Effects on Knee Osteoarthritis and Related Pain. In: Watson RR, Preedy VR, editors. *Bioactive Food as Dietary Interventions for Arthritis and Related Inflammatory Diseases (Second Edition)*. Academic Press, 2019. pp. 223–232. doi:10.1016/B978-0-12-813820-5.00012-X.
- [20] Dai Z, Niu J, Zhang Y, Jacques P, Felson DT. Dietary intake of fibre and risk of knee osteoarthritis in two US prospective cohorts. *Ann Rheum Dis* 2017;76:1411–1419.
- [21] Dance A. Why the sexes don't feel pain the same way. *Nature* 2019;567:448–450.
- [22] Emery CF, Olson KL, Bodine A, Lee V, Habash DL. Dietary intake mediates the relationship of body fat to pain: *PAIN* 2017;158:273–277.
- [23] Fayaz A, Croft P, Langford RM, Donaldson LJ, Jones GT. Prevalence of chronic pain in the UK: a systematic review and meta-analysis of population studies. *BMJ Open* 2016;6.  
doi:10.1136/bmjopen-2015-010364.
- [24] Fernandez M, Colodro-Conde L, Hartvigsen J, Ferreira ML, Refshauge KM, Pinheiro MB, Ordoñana JR, Ferreira PH. Chronic low back pain and the risk of depression or anxiety symptoms: insights from a longitudinal twin study. *The Spine Journal* 2017;17:905–912.
- [25] Freidin M, Tsepilov Y, Palmer M, Karssen L, Suri P, Aulchenko Y, Williams F. Insight into the genetic architecture of back pain and its risk factors from a study of 509,000 individuals. *Pain* 2019;Publish Ahead of Print. doi:10.1097/j.pain.0000000000001514.
- [26] Gaskin DJ, Richard P, Walburn J. The Economical Impact of Pain. In: Saba L, editor. *Neuroimaging of Pain*. Cham: Springer International Publishing, 2017. pp. 1–17.  
doi:10.1007/978-3-319-48046-6\_1.
- [27] GWAS Catalog - NMT1. n.d. Available: <https://www.ebi.ac.uk/gwas/genes/NMT1>. Accessed 20 Jan 2020.
- [28] Hasenbring MI, Andrews NE, Ebenbichler G. Overactivity in Chronic Pain, the Role of Pain-related Endurance and Neuromuscular Activity: An Interdisciplinary, Narrative Review. *Clin J Pain* 2020;36:162–171.

- [29] Haworth S, Kho PF, Holgerson PL, Hwang L-D, Timpson NJ, Rentería ME, Johansson I, Cuellar-Partida G. Inference and visualization of phenome-wide causal relationships using genetic data: an application to dental caries and periodontitis. *bioRxiv* 2020:865956.
- [30] Heuch I, Hagen K, Heuch I, Nygaard Ø, Zwart J-A. The Impact of Body Mass Index on the Prevalence of Low Back Pain. *Spine* 2010;35:764–768.
- [31] Hitt HC, McMillen RC, Thornton-Neaves T, Koch K, Cosby AG. Comorbidity of Obesity and Pain in a General Population: Results from the Southern Pain Prevalence Study. *The Journal of Pain* 2007;8:430–436.
- [32] Holmes A, Christelis N, Arnold C. Depression and chronic pain. *Medical Journal of Australia* 2013;199. doi:10.5694/mja12.10589.
- [33] Hussain SM, Urquhart DM, Wang Y, Shaw JE, Magliano DJ, Wluka AE, Cicuttini FM. Fat mass and fat distribution are associated with low back pain intensity and disability: results from a cohort study. *Arthritis Res Ther* 2017;19. doi:10.1186/s13075-017-1242-z.
- [34] Jackson T, Thomas S, Stabile V, Shotwell M, Han X, McQueen K. A Systematic Review and Meta-Analysis of the Global Burden of Chronic Pain Without Clear Etiology in Low- and Middle-Income Countries: Trends in Heterogeneous Data and a Proposal for New Assessment Methods. *Anesth Analg* 2016;123:739–748.
- [35] Jaracz J, Gattner K, Jaracz K, Górna K. Unexplained Painful Physical Symptoms in Patients with Major Depressive Disorder: Prevalence, Pathophysiology and Management. *CNS Drugs* 2016;30:293–304.
- [36] Johnston KJA, Adams MJ, Nicholl BI, Ward J, Strawbridge RJ, Ferguson A, McIntosh AM, Bailey MES, Smith DJ. Genome-wide association study of multisite chronic pain in UK Biobank. *PLoS Genet* 2019;15. doi:10.1371/journal.pgen.1008164.
- [37] Kato K, Sullivan PF, Evengård B, Pedersen NL. Importance of genetic influences on chronic widespread pain. *Arthritis & Rheumatism* 2006;54:1682–1686.
- [38] Khan WU, Michelini G, Battaglia M. Twin studies of the covariation of pain with depression and anxiety: A systematic review and re-evaluation of critical needs. *Neuroscience & Biobehavioral Reviews* 2020;111:135–148.
- [39] Kichaev G, Bhatia G, Loh P-R, Gazal S, Burch K, Freund MK, Schoech A, Pasaniuc B, Price AL. Leveraging Polygenic Functional Enrichment to Improve GWAS Power. *The American Journal of Human Genetics* 2019;104:65–75.
- [40] Kim SK. Identification of 613 new loci associated with heel bone mineral density and a polygenic risk score for bone mineral density, osteoporosis and fracture. *PLoS ONE* 2018;13:e0200785.
- [41] Kirsch Micheletti J, Bláfoss R, Sundstrup E, Bay H, Pastre CM, Andersen LL. Association between lifestyle and musculoskeletal pain: cross-sectional study among 10,000 adults from the general working population. *BMC Musculoskelet Disord* 2019;20:609.
- [42] Klingbeil EA, Cawthon C, Kirkland R, de La Serre CB. Potato-Resistant Starch Supplementation Improves Microbiota Dysbiosis, Inflammation, and Gut–Brain Signaling in High Fat-Fed Rats. *Nutrients* 2019;11:2710.

- [43] Kvalheim S, Sandven I, Hagen K, Zwart J-A. Smoking as a risk factor for chronic musculoskeletal complaints is influenced by age. *The HUNT study*. *Pain* 2013;154:1073–1079.
- [44] Lalanne L, Nicot C, Lang J-P, Bertschy G, Salvat E. Experience of the use of Ketamine to manage opioid withdrawal in an addicted woman: a case report. *BMC Psychiatry* 2016;16:395.
- [45] Lambert-Porcheron S, Normand S, Blond E, Sothier M, Roth H, Meynier A, Vinoy S, Laville M, Nazare J-A. Modulation of Starch Digestibility in Breakfast Cereals Consumed by Subjects with Metabolic Risk: Impact on Markers of Oxidative Stress and Inflammation during Fasting and the Postprandial Period. *Molecular Nutrition & Food Research* 2017;61:1700212.
- [46] LEMD2 - LEM domain-containing protein 2 - Homo sapiens (Human) - LEMD2 gene & protein. n.d. Available: <https://www.uniprot.org/uniprot/Q8NC56#function>. Accessed 19 Jul 2019.
- [47] Loh P-R, Tucker G, Bulik-Sullivan BK, Vilhjálmsson BJ, Finucane HK, Salem RM, Chasman DI, Ridker PM, Neale BM, Berger B, Patterson N, Price AL. Efficient Bayesian mixed model analysis increases association power in large cohorts. *Nat Genet* 2015;47:284–290.
- [48] Macfarlane GJ, Barnish MS, Jones GT. Persons with chronic widespread pain experience excess mortality: longitudinal results from UK Biobank and meta-analysis. *Annals of the Rheumatic Diseases* 2017;76:1815–1822.
- [49] Macfarlane GJ, Beasley M, Smith BH, Jones GT, Macfarlane TV. Can large surveys conducted on highly selected populations provide valid information on the epidemiology of common health conditions? An analysis of UK Biobank data on musculoskeletal pain. *British Journal of Pain* 2015;9:203–212.
- [50] Margraf A, Herter JM, Kühne K, Stadtmann A, Ermert T, Wenk M, Meersch M, Van Aken H, Zarbock A, Rossaint J. 6% Hydroxyethyl starch (HES 130/0.4) diminishes glycocalyx degradation and decreases vascular permeability during systemic and pulmonary inflammation in mice. *Critical Care* 2018;22:111.
- [51] McIntosh AM, Hall LS, Zeng Y, Adams MJ, Gibson J, Wigmore E, Hagenaars SP, Davies G, Fernandez-Pujals AM, Campbell AI, Clarke T-K, Hayward C, Haley CS, Porteous DJ, Deary IJ, Smith DJ, Nicholl BI, Hinds DA, Jones AV, Scollen S, Meng W, Smith BH, Hocking LJ. Genetic and Environmental Risk for Chronic Pain and the Contribution of Risk Variants for Major Depressive Disorder: A Family-Based Mixed-Model Analysis. *PLOS Medicine* 2016;13:e1002090.
- [52] McVinnie DS. Obesity and pain. *British Journal of Pain* 2013;7:163–170.
- [53] Meloto CB, Benavides R, Lichtenwalter RN, Wen X, Tugarinov N, Zorina-Lichtenwalter K, Chabot-Doré A-J, Piltonen MH, Cattaneo S, Verma V, Klares RI, Khoury S, Parisien M, Diatchenko L. Human pain genetics database: a resource dedicated to human pain genetics research. *PAIN* 2018;159:749–763.
- [54] Mills SEE, Nicolson KP, Smith BH. Chronic pain: a review of its epidemiology and associated factors in population-based studies. *British Journal of Anaesthesia* 2019;123:e273–e283.
- [55] Morris JA, Kemp JP, Youten SE, Laurent L, Logan JG, Chai RC, Vulpescu NA, Forgetta V, Kleinman A, Mohanty ST, Sergio CM, Quinn J, Nguyen-Yamamoto L, Luco A-L, Vijay J, Simon M-M, Pramatarova A, Medina-Gomez C, Trajanoska K, Ghirardello EJ, Butterfield NC, Curry KF,

- Leitch VD, Sparkes PC, Adoum A-T, Mannan NS, Komla-Ebri DSK, Pollard AS, Dewhurst HF, Hassall TAD, Beltejar M-JG, 23andMe Research Team, Adams DJ, Vaillancourt SM, Kaptoge S, Baldock P, Cooper C, Reeve J, Ntzeni EE, Evangelou E, Ohlsson C, Karasik D, Rivadeneira F, Kiel DP, Tobias JH, Gregson CL, Harvey NC, Grundberg E, Goltzman D, Adams DJ, Lelliott CJ, Hinds DA, Ackert-Bicknell CL, Hsu Y-H, Maurano MT, Croucher PJ, Williams GR, Bassett JHD, Evans DM, Richards JB. An atlas of genetic influences on osteoporosis in humans and mice. *Nat Genet* 2019;51:258–266.
- [56] Narouze S, Souzdanitski D. Obesity and Chronic Pain: Systematic Review of Prevalence and Implications for Pain Practice. *Regional Anesthesia and Pain Medicine* 2015;40:91–111.
- [57] Neale Lab - UK Biobank. Neale lab n.d. Available: <http://www.nealelab.is/uk-biobank>. Accessed 11 Mar 2019.
- [58] Niculescu AB, Le-Niculescu H, Levey DF, Roseberry K, Soe KC, Rogers J, Khan F, Jones T, Judd S, McCormick MA, Wessel AR, Williams A, Kurian SM, White FA. Towards precision medicine for pain: diagnostic biomarkers and repurposed drugs. *Mol Psychiatry* 2019;24:501–522.
- [59] O'Connor LJ, Price AL. Distinguishing genetic correlation from causation across 52 diseases and complex traits. *Nature Genetics* 2018;50:1728.
- [60] Okifuji A, Hare BD. The association between chronic pain and obesity. *J Pain Res* 2015;8:399–408.
- [61] Packiasabapathy S, Sadhasivam S. Gender, genetics, and analgesia: understanding the differences in response to pain relief. *J Pain Res* 2018;11:2729–2739.
- [62] Paley CA, Johnson MI. Physical Activity to Reduce Systemic Inflammation Associated With Chronic Pain and Obesity: A Narrative Review. *The Clinical Journal of Pain* 2016;32:365–370.
- [63] Pers TH, Karjalainen JM, Chan Y, Westra H-J, Wood AR, Yang J, Lui JC, Vedantam S, Gustafsson S, Esko T, Frayling T, Speliotes EK, Genetic Investigation of AnTC, Boehnke M, Raychaudhuri S, Fehrmann RSN, Hirschhorn JN, Franke L. Biological interpretation of genome-wide association studies using predicted gene functions. *Nature communications* 2015;6:5890.
- [64] Petrini L, Matthiesen ST, Arendt-Nielsen L. The Effect of Age and Gender on Pressure Pain Thresholds and Suprathreshold Stimuli. *Perception* 2015;44:587–596.
- [65] Raffaelli W, Arnaudo E. Pain as a disease: an overview. *JPR* 2017;Volume 10:2003–2008.
- [66] Rieb LM, Norman WV, Martin RE, Berkowitz J, Wood E, McNeil R, Milloy M-J. Withdrawal-associated injury site pain (WISP): a descriptive case series of an opioid cessation phenomenon. *PAIN* 2016;157:2865.
- [67] Ruderfer DM, Ripke S, McQuillin A, Boocock J, Stahl EA, Whitehead Pavlides JM, Mullins N, Charney AW, Ori APS, Olde Loohuis LM, Domenici E, Di Florio A, Papiol S, Kalman JL, Trubetskoy V, Adolfsson R, Agartz I, Agerbo E, Akil H, Albani D, Albus M, Alda M, Alexander M, Alliey-Rodriguez N, Als TD, Amin F, Anjorin A, Arranz MJ, Awasthi S, Bacanu SA, Badner JA, Baekvad-Hansen M, Bakker S, Band G, Barchas JD, Barroso I, Bass N, Bauer M, Baune BT, Begemann M, Bellenguez C, Belliveau RA, Bellivier F, Bender S, Bene J, Bergen SE, Berrettini WH, Bevilacqua E, Biernacka JM, Bigdeli TB, Black DW, Blackburn H, Blackwell JM, Blackwood DH, Pedersen CB, Boehnke M, Boks M, Borglum AD, Bramon E, Breen G, Brown MA, Bruggeman R, Buccola NG, Buckner RL, Budde M, Bulik-Sullivan B, Bumpstead SJ, Bunney W,

Burmeister M, Buxbaum JD, Bybjerg-Grauholm J, Byerley W, Cahn W, Cai G, Cairns MJ, Champion D, Cantor RM, Carr VJ, Carrera N, Casas JP, Casas M, Catts SV, Cervantes P, Chambert KD, Chan RC, Chen EY, Chen RY, Cheng W, Cheung EF, Chong SA, Clarke T-K, Cloninger CR, Cohen D, Cohen N, Coleman JRI, Collier DA, Cormican P, Coryell W, Craddock N, Craig DW, Crespo-Facorro B, Crowley JJ, Cruceanu C, Curtis D, Czerski PM, Dale AM, Daly MJ, Dannowski U, Darvasi A, Davidson M, Davis KL, de Leeuw CA, Degenhardt F, Del Favero J, DeLisi LE, Deloukas P, Demontis D, DePaulo JR, di Forti M, Dikeos D, Dinan T, Djurovic S, Dobbryn AL, Donnelly P, Donohoe G, Drapeau E, Dronov S, Duan J, Dudbridge F, Duncanson A, Edenberg H, Edkins S, Ehrenreich H, Eichhammer P, Elvsashagen T, Eriksson J, Escott-Price V, Esko T, Essioux L, Etain B, Fan CC, Farh K-H, Farrell MS, Flickinger M, Foroud TM, Forty L, Frank J, Franke L, Fraser C, Freedman R, Freeman C, Freimer NB, Friedman JI, Fromer M, Frye MA, Fullerton JM, Gade K, Garnham J, Gaspar HA, Gejman PV, Genovese G, Georgieva L, Giambartolomei C, Giannoulatos E, Giegling I, Gill M, Gillman M, Pedersen MG, Giusti-Rodriguez P, Godard S, Goes F, Goldstein JI, Gopal S, Gordon SD, Gordon-Smith K, Gratten J, Gray E, Green EK, Green MJ, Greenwood TA, Grigoriou-Serbanescu M, Grove J, Guan W, Gurling H, Parra JG, Gwilliam R, de Haan L, Hall J, Hall M-H, Hammer C, Hammond N, Hamshere ML, Hansen M, Hansen T, Haroutunian V, Hartmann AM, Hauser J, Hautzinger M, Heilbronner U, Hellenthal G, Henskens FA, Herms S, Hipolito M, Hirschhorn JN, Hoffmann P, Hollegaard MV, Hougaard DM, Huang H, Huckins L, Hultman CM, Hunt SE, Ikeda M, Iwata N, Iyegbe C, Jablensky AV, Jamain S, Jankowski J, Jayakumar A, Joa I, Jones I, Jones LA, Jonsson EG, Julia A, Jureus A, Kahler AK, Kahn RS, Kalaydjieva L, Kandaswamy R, Karachanak-Yankova S, Karjalainen J, Karlsson R, Kavanagh D, Keller MC, Kelly BJ, Kelsoe J, Kennedy JL, Khrunin A, Kim Y, Kirov G, Kittel-Schneider S, Klovins J, Knight J, Knott SV, Knowles JA, Kogevinas M, Konte B, Kravariti E, Kucinskas V, Kucinskiene ZA, Kupka R, Kuzelova-Ptackova H, Landen M, Langford C, Laurent C, Lawrence J, Lawrie S, Lawson WB, Leber M, Leboyer M, Lee PH, Chee Keong JL, Legge SE, Lencz T, Lerer B, Levinson DF, Levy SE, Lewis CM, Li JZ, Li M, Li QS, Li T, Liang K-Y, Liddle J, Lieberman J, Limborska S, Lin K, Linszen DH, Lissowska J, Liu C, Liu J, Lonnqvist J, Loughland CM, Lubinski J, Lucae S, Macek M, MacIntyre DJ, Magnusson PK, Maher BS, Mahon PB, Maier W, Malhotra AK, Mallet J, Malt UF, Markus HS, Marsal S, Martin NG, Mata I, Mathew CG, Mattheisen M, Mattingsdal M, Mayoral F, McCann OT, McCarley RW, McCarroll SA, McCarthy MI, McDonald C, McElroy SL, McGuffin P, McInnis MG, McIntosh AM, McKay JD, McMahon FJ, Medeiros H, Medland SE, Meier S, Meijer CJ, Melegh B, Melle I, Meng F, Meshulam-Gately RI, Metspalu A, Michie PT, Milani L, Milanova V, Mitchell PB, Mokrab Y, Montgomery GW, Moran JL, Morken G, Morris DW, Mors O, Mortensen PB, Mowry BJ, Mühleisen TW, Müller-Myhsok B, Murphy KC, Murray RM, Myers RM, Myin-Germeyns I, Neale BM, Nelis M, Nenadic I, Nertney DA, Nestadt G, Nicodemus KK, Nievergelt CM, Nikitina-Zake L, Nimgaonkar V, Nisenbaum L, Nordentoft M, Nordin A, Nöthen MM, Nwulia EA, O'Callaghan E, O'Donovan C, O'Dushlaine C, O'Neill FA, Oedegaard KJ, Oh S-Y, Olincy A, Olsen L, Oruc L, Van Os J, Owen MJ, Paciga SA, Palmer CNA, Palotie A, Pantelis C, Papadimitriou GN, Parkhomenko E, Pato C, Pato MT, Paunio T, Pearson R, Perkins DO, Perlis RH, Perry A, Pers TH, Petryshen TL, Pfennig A, Picchioni M, Pietiläinen O, Pimm J, Pirinen M, Plomin R, Pocklington AJ, Posthuma D, Potash JB, Potter SC, Powell J, Price A, Pulver AE, Purcell SM, Quested D, Ramos-Quiroga JA, Rasmussen HB, Rautanen A, Ravindrarajah R, Regeer EJ, Reichenberg A, Reif A, Reimers MA, Ribases M, Rice JP, Richards AL, Ricketts M, Riley BP, Rivas F, Rivera M, Roffman JL, Rouleau GA, Roussos P, Rujescu D, Salomaa V, Sanchez-Mora C, Sanders AR, Sawcer SJ, Schall U, Schatzberg AF, Scheftner WA, Schofield PR, Schork NJ, Schwab SG, Scolnick EM, Scott LJ, Scott RJ, Seidman LJ, Serretti A, Sham PC, Weickert CS, Shekhtman T, Shi J, Shilling PD, Sigurdsson E, Silverman JM, Sim K, Slaney C, Slominsky P, Smeland OB, Smoller JW, So H-C, Sobell JL, Soderman E, Hansen CS, Spencer CCA, Spijker AT, St Clair D, Stefansson H, Stefansson K, Steinberg S, Stogmann E, Stordal E, Strange A, Straub RE, Strauss JS, Streit F, Strengman E, Strohmaier J, Stroup TS, Su Z,



- Subramaniam M, Suvisaari J, Svrakic DM, Szatkiewicz JP, Szelinger S, Tashakkori-Ghanbaria A, Thirumalai S, Thompson RC, Thorgeirsson TE, Toncheva D, Tooney PA, Tosato S, Touloupoulou T, Trembath RC, Treutlein J, Trubetskoy V, Turecki G, Vaaler AE, Vedder H, Vieta E, Vincent J, Visscher PM, Viswanathan AC, Vukcevic D, Waddington J, Waller M, Walsh D, Walshe M, Walters JT, Wang D, Wang Q, Wang W, Wang Y, Watson SJ, Webb BT, Weickert TW, Weinberger DR, Weisbrod M, Weiser M, Werge T, Weston P, Whittaker P, Widaa S, Wiersma D, Wildenauer DB, Williams NM, Williams S, Witt SH, Wolen AR, Wong EH, Wood NW, Wormley BK, Wu JQ, Xi S, Xu W, Young AH, Zai CC, Zandi P, Zhang P, Zheng X, Zimprich F, Zollner S, Corvin A, Fanous AH, Cichon S, Rietschel M, Gershon ES, Schulze TG, Cuellar-Barboza AB, Forstner AJ, Holmans PA, Nurnberger JI, Andreassen OA, Lee SH, O'Donovan MC, Sullivan PF, Ophoff RA, Wray NR, Sklar P, Kendler KS. Genomic dissection of bipolar disorder and schizophrenia including 28 subphenotypes. *Cell* 2018;173:1705-1715.e16.
- [68] Sá KN, Moreira L, Baptista AF, Yeng LT, Teixeira MJ, Galhardoni R, de Andrade DC. Prevalence of chronic pain in developing countries: systematic review and meta-analysis. *PAIN Reports* 2019;4:e779.
- [69] Sato T, Konomi K, Yamasaki S, Aratani S, Tsuchimochi K, Yokouchi M, Masuko-Hongo K, Yagishita N, Nakamura H, Komiya S, Beppu M, Aoki H, Nishioka K, Nakajima T. Comparative analysis of gene expression profiles in intact and damaged regions of human osteoarthritic cartilage. *Arthritis Rheum* 2006;54:808–817.
- [70] Sheng J, Liu S, Wang Y, Cui R, Zhang X. The Link between Depression and Chronic Pain: Neural Mechanisms in the Brain. *Neural Plasticity* 2017;2017:1–10.
- [71] Siddall PJ, Cousins MJ. Persistent Pain as a Disease Entity: Implications for Clinical Management. *Anesthesia & Analgesia* 2004;99:510–520.
- [72] Sorge RE, Totsch SK. Sex Differences in Pain. *J Neurosci Res* 2017;95:1271–1281.
- [73] Souza JB de, Grossmann E, Perissinotti DMN, Oliveira Junior JO de, Fonseca PRB da, Posso I de P. Prevalence of Chronic Pain, Treatments, Perception, and Interference on Life Activities: Brazilian Population-Based Survey. *Pain Research and Management* 2017. doi:10.1155/2017/4643830.
- [74] Stone AA, Broderick JE. Obesity and Pain Are Associated in the United States. *Obesity* 2012;20:1491–1495.
- [75] Suri P, Palmer MR, Tsepilov YA, Freidin MB, Boer CG, Yau MS, Evans DS, Gelemanovic A, Bartz TM, Nethander M, Arbeeve L, Karssen L, Neogi T, Campbell A, Mellstrom D, Ohlsson C, Marshall LM, Orwoll E, Uitterlinden A, Rotter JJ, Lauc G, Psaty BM, Karlsson MK, Lane NE, Jarvik GP, Polasek O, Hochberg M, Jordan JM, Van Meurs JBJ, Jackson R, Nielson CM, Mitchell BD, Smith BH, Hayward C, Smith NL, Aulchenko YS, Williams FMK. Genome-wide meta-analysis of 158,000 individuals of European ancestry identifies three loci associated with chronic back pain. *PLoS Genet* 2018;14. doi:10.1371/journal.pgen.1007601.
- [76] Swingle TE, Waters JG, Davidson RK, Pennington CJ, Puente XS, Darrah C, Cooper A, Donnell ST, Guile GR, Wang W, Clark IM. Degradome expression profiling in human articular cartilage. *Arthritis Res Ther* 2009;11:R96.
- [77] The cost of pain in Australia | Deloitte Australia | Deloitte Access Economics, Healthcare, Public sector. Deloitte Australia n.d. Available:

<https://www2.deloitte.com/au/en/pages/economics/articles/cost-pain-australia.html>.  
Accessed 6 Apr 2020.

- [78] The Genotype-Tissue Expression (GTEx) project. *Nat Genet* 2013;45:580–585.
- [79] Tramadol to Reduce Opioid Withdrawal Symptoms. n.d. Available: <https://clinicaltrials.gov/ct2/show/NCT00142896>. Accessed 19 Jan 2020.
- [80] Trampush JW, Yang MLZ, Yu J, Knowles E, Davies G, Liewald DC, Starr JM, Djurovic S, Melle I, Sundet K, Christoforou A, Reinvang I, DeRosse P, Lundervold AJ, Steen VM, Espeseth T, R  ikk  nen K, Widen E, Palotie A, Eriksson JG, Giegling I, Konte B, Roussos P, Giakoumaki S, Burdick KE, Payton A, Ollier W, Horan M, Chiba-Falek O, Attix DK, Need AC, Cirulli ET, Voineskos AN, Stefanis NC, Avramopoulos D, Hatzimanolis A, Arking DE, Smyrnis N, Bilder RM, Freimer NA, Cannon TD, London E, Poldrack RA, Sabb FW, Congdon E, Conley ED, Scult MA, Dickinson D, Straub RE, Donohoe G, Morris D, Corvin A, Gill M, Hariri AR, Weinberger DR, Pendleton N, Bitsios P, Rujescu D, Lahti J, Hellard SL, Keller MC, Andreassen OA, Deary IJ, Glahn DC, Malhotra AK, Lencz T. GWAS meta-analysis reveals novel loci and genetic correlates for general cognitive function: a report from the COGENT consortium. *Mol Psychiatry* 2017;22:336–345.
- [81] Treede R-D, Rief W, Barke A, Aziz Q, Bennett MI, Benoliel R, Cohen M, Evers S, Finnerup NB, First MB, Giamberardino MA, Kaasa S, Korwisi B, Kosek E, Lavand'homme P, Nicholas M, Perrot S, Scholz J, Schug S, Smith BH, Svensson P, Vlaeyen JWS, Wang S-J. Chronic pain as a symptom or a disease: the IASP Classification of Chronic Pain for the International Classification of Diseases (ICD-11). *PAIN* 2019;160:19.
- [82] Trivedi MH. The Link Between Depression and Physical Symptoms. *Prim Care Companion J Clin Psychiatry* 2004;6:12–16.
- [83] UKBB GWAS Imputed v3 - File Manifest Release 20180731. Google Docs n.d. Available: [https://docs.google.com/spreadsheets/d/1kvPoupSzsSFBNSztMzl04xMoSC3Kcx3CrjVf4yBmESU/edit?ts=5b5f17db&usp=embed\\_facebook](https://docs.google.com/spreadsheets/d/1kvPoupSzsSFBNSztMzl04xMoSC3Kcx3CrjVf4yBmESU/edit?ts=5b5f17db&usp=embed_facebook). Accessed 5 Nov 2019.
- [84] Urquhart DM, Berry P, Wluka AE, Strauss BJ, Wang Y, Proietto J, Jones G, Dixon JB, Cicuttini FM. 2011 Young Investigator Award Winner: Increased Fat Mass Is Associated With High Levels of Low Back Pain Intensity and Disability. *Spine* 2011;36:1320–1325.
- [85] Vellucci R. Heterogeneity of Chronic Pain. *Clin Drug Investig* 2012;32:3–10.
- [86] Vos T, Allen C, Arora M, Barber RM, Bhutta ZA, Brown A, Carter A, Casey DC, Charlson FJ, Chen AZ, Coggeshall M, Cornaby L, Dandona L, Dicker DJ, Dilegge T, Erskine HE, Ferrari AJ, Fitzmaurice C, Fleming T, Forouzanfar MH, Fullman N, Gething PW, Goldberg EM, Graetz N, Haagsma JA, Hay SI, Johnson CO, Kassebaum NJ, Kawashima T, Kemmer L, Khalil IA, Kinfu Y, Kyu HH, Leung J, Liang X, Lim SS, Lopez AD, Lozano R, Marczak L, Mensah GA, Mokdad AH, Naghavi M, Nguyen G, Nsoesie E, Olsen H, Pigott DM, Pinho C, Rankin Z, Reinig N, Salomon JA, Sandar L, Smith A, Stanaway J, Steiner C, Teeple S, Thomas BA, Troeger C, Wagner JA, Wang H, Wanga V, Whiteford HA, Zoeckler L, Abajobir AA, Abate KH, Abbafati C, Abbas KM, Abd-Allah F, Abraham B, Abubakar I, Abu-Raddad LJ, Abu-Rmeileh NME, Ackerman IN, Adebisi AO, Ademi Z, Adou AK, Afanvi KA, Agardh EE, Agarwal A, Kiadaliri AA, Ahmadi H, Ajala ON, Akinyemi RO, Akseer N, Al-Aly Z, Alam K, Alam NKM, Aldhahri SF, Alegretti MA, Alemu ZA, Alexander LT, Alhabib S, Ali R, Alkerwi A, Alla F, Allebeck P, Al-Raddadi R, Alsharif U, Altirkawi KA, Alvis-Guzman N, Amare AT, Amberbir A, Amini H, Ammar W, Amrock SM, Andersen HH,


Anderson GM, Anderson BO, Antonio CAT, Aregay AF, Ärnlov J, Artaman A, Asayesh H, Assadi R, Atique S, Avokpaho EFGA, Awasthi A, Quintanilla BPA, Azzopardi P, Bacha U, Badawi A, Balakrishnan K, Banerjee A, Barac A, Barker-Collo SL, Bärnighausen T, Barregard L, Barrero LH, Basu A, Bazargan-Hejazi S, Beghi E, Bell B, Bell ML, Bennett DA, Bensenor IM, Benzin H, Berhane A, Bernabé E, Betsu BD, Beyene AS, Bhala N, Bhatt S, Biadgilign S, Bienhoff K, Bikbov B, Biryukov S, Bisanzio D, Bjertness E, Blore J, Borschmann R, Boufous S, Brainin M, Brazinova A, Breitborde NJK, Brown J, Buchbinder R, Buckle GC, Butt ZA, Calabria B, Campos-Nonato IR, Campuzano JC, Carabin H, Cárdenas R, Carpenter DO, Carrero JJ, Castañeda-Orjuela CA, Rivas JC, Catalá-López F, Chang J-C, Chiang PP-C, Chibueze CE, Chisumpa VH, Choi J-YJ, Chowdhury R, Christensen H, Christopher DJ, Ciobanu LG, Cirillo M, Coates MM, Colquhoun SM, Cooper C, Cortinovis M, Crump JA, Damtew SA, Dandona R, Daoud F, Dargan PI, das Neves J, Davey G, Davis AC, Leo DD, Degenhardt L, Gobbo LCD, Dellavalle RP, Deribe K, Deribew A, Derrett S, Jarlais DCD, Dharmaratne SD, Dhillon PK, Diaz-Torné C, Ding EL, Driscoll TR, Duan L, Dubey M, Duncan BB, Ebrahimi H, Ellenbogen RG, Elyazar I, Endres M, Endries AY, Ermakov SP, Eshtrati B, Estep K, Farid TA, Farinha CS e S, Faro A, Farvid MS, Farzadfar F, Feigin VL, Felson DT, Fereshtehnejad S-M, Fernandes JG, Fernandes JC, Fischer F, Fitchett JRA, Foreman K, Fowkes FGR, Fox J, Franklin RC, Friedman J, Frostad J, Fürst T, Futran ND, Gabbe B, Ganguly P, Gankpé FG, Gebre T, Gebrehiwot TT, Gebremedhin AT, Geleijnse JM, Gessner BD, Gibney KB, Ginawi IAM, Giref AZ, Giroud M, Gishu MD, Giussani G, Glaser E, Godwin WW, Gomez-Dantes H, Gona P, Goodridge A, Gopalani SV, Gotay CC, Goto A, Gouda HN, Grainger R, Greaves F, Guillemin F, Guo Y, Gupta R, Gupta R, Gupta V, Gutiérrez RA, Haile D, Hailu AD, Hailu GB, Halasa YA, Hamadeh RR, Hamidi S, Hammami M, Hancock J, Handal AJ, Hankey GJ, Hao Y, Harb HL, Harikrishnan S, Haro JM, Havmoeller R, Hay RJ, Heredia-Pi IB, Heydarpour P, Hoek HW, Horino M, Horita N, Hosgood HD, Hoy DG, Htet AS, Huang H, Huang JJ, Huynh C, Iannarone M, Iburg KM, Innos K, Inoue M, Iyer VJ, Jacobsen KH, Jahanmehr N, Jakovljevic MB, Javanbakht M, Jayaraman SP, Jayatilleke AU, Jee SH, Jeemon P, Jensen PN, Jiang Y, Jibat T, Jimenez-Corona A, Jin Y, Jonas JB, Kabir Z, Kalkonde Y, Kamal R, Kan H, Karch A, Karema CK, Karimkhani C, Kasaeian A, Kaul A, Kawakami N, Keiyoro PN, Kemp AH, Keren A, Kesavachandran CN, Khader YS, Khan AR, Khan EA, Khang Y-H, Khera S, Khoja TAM, Khubchandani J, Kielsing C, Kim P, Kim C, Kim D, Kim YJ, Kisson N, Knibbs LD, Knudsen AK, Kokubo Y, Kolte D, Kopec JA, Kosen S, Kotsakis GA, Koul PA, Koyanagi A, Kravchenko M, Defo BK, Bicer BK, Kudom AA, Kuipers EJ, Kumar GA, Kutz M, Kwan GF, Lal A, Laloo R, Lallukka T, Lam H, Lam JO, Langan SM, Larsson A, Lavados PM, Leasher JL, Leigh J, Leung R, Levi M, Li Y, Li Y, Liang J, Liu S, Liu Y, Lloyd BK, Lo WD, Logroscino G, Looker KJ, Lotufo PA, Lunevicius R, Lyons RA, Mackay MT, Magdy M, Razek AE, Mahdavi M, Majdan M, Majeed A, Malekzadeh R, Marcenes W, Margolis DJ, Martinez-Raga J, Masiye F, Massano J, McGarvey ST, McGrath JJ, McKee M, McMahon BJ, Meaney PA, Mehari A, Mejia-Rodriguez F, Mekonnen AB, Melaku YA, Memiah P, Memish ZA, Mendoza W, Meretoja A, Meretoja TJ, Mhimbira FA, Millier A, Miller TR, Mills EJ, Mirarefin M, Mitchell PB, Mock CN, Mohammadi A, Mohammed S, Monasta L, Hernandez JCM, Montico M, Mooney MD, Moradi-Lakeh M, Morawska L, Mueller UO, Mullany E, Mumford JE, Murdoch ME, Nachega JB, Nagel G, Naheed A, Naldi L, Nangia V, Newton JN, Ng M, Ngalesoni FN, Nguyen QL, Nisar MI, Pete PMN, Nolla JM, Norheim OF, Norman RE, Norrving B, Nunes BP, Ogbo FA, Oh I-H, Ohkubo T, Olivares PR, Olusanya BO, Olusanya JO, Ortiz A, Osman M, Ota E, Pa M, Park E-K, Parsaeian M, de Azeredo Passos VM, Caicedo AJP, Patten SB, Patton GC, Pereira DM, Perez-Padilla R, Perico N, Pesudovs K, Petzold M, Phillips MR, Piel FB, Pillay JD, Pishgar F, Plass D, Platts-Mills JA, Polinder S, Pond CD, Popova S, Poulton RG, Pourmalek F, Prabhakaran D, Prasad NM, Qorbani M, Rabiee RHS, Radfar A, Rafay A, Rahimi K, Rahimi-Movaghar V, Rahman M, Rahman MHU, Rahman SU, Rai RK, Rajsic S, Ram U, Rao P, Refaat AH, Reitsma MB, Remuzzi G, Resnikoff S, Reynolds A, Ribeiro AL, Blancas MJR, Roba HS, Rojas-Rueda D, Ronfani L, Roshandel G, Roth GA, Rothenbacher D, Roy A, Sagar R, Sahathevan R, Sanabria JR, Sanchez-Niño MD, Santos IS,

Santos JV, Sarmiento-Suarez R, Sartorius B, Satpathy M, Savic M, Sawhney M, Schaub MP, Schmidt MI, Schneider IJC, Schöttker B, Schwebel DC, Scott JG, Seedat S, Sepanlou SG, Servan-Mori EE, Shackelford KA, Shaheen A, Shaikh MA, Sharma R, Sharma U, Shen J, Shepard DS, Sheth KN, Shibuya K, Shin M-J, Shiri R, Shiue I, Shrimme MG, Sigfusdottir ID, Silva DAS, Silveira DGA, Singh A, Singh JA, Singh OP, Singh PK, Sivonda A, Skirbekk V, Skogen JC, Sligar A, Sliwa K, Soljak M, Søreide K, Sorensen RJD, Soriano JB, Sposato LA, Sreeramareddy CT, Stathopoulou V, Steel N, Stein DJ, Steiner TJ, Steinke S, Stovner L, Stroumpoulis K, Sunguya BF, Sur P, Swaminathan S, Sykes BL, Szeke CEI, Tabarés-Seisdedos R, Takala JS, Tandon N, Tanne D, Tavakkoli M, Taye B, Taylor HR, Ao BJT, Tedla BA, Terkawi AS, Thomson AJ, Thorne-Lyman AL, Thrift AG, Thurston GD, Tobe-Gai R, Tonelli M, Topor-Madry R, Topouzis F, Tran BX, Truelsen T, Dimbuene ZT, Tsilimbaris M, Tura AK, Tuzcu EM, Tyrovolas S, Ukwaja KN, Undurraga EA, Uneke CJ, Uthman OA, van Gool CH, Varakin YY, Vasankari T, Venketasubramanian N, Verma RK, Violante FS, Vladimirov SK, Vlassov VV, Vollset SE, Wagner GR, Waller SG, Wang L, Watkins DA, Weichenthal S, Weiderpass E, Weintraub RG, Werdecker A, Westerman R, White RA, Williams HC, Wiysonge CS, Wolfe CDA, Won S, Woodbrook R, Wubshet M, Xavier D, Xu G, Yadav AK, Yan LL, Yano Y, Yaseri M, Ye P, Yebyo HG, Yip P, Yonemoto N, Yoon S-J, Younis MZ, Yu C, Zaidi Z, Zaki MES, Zeeb H, Zhou M, Zodepy S, Zuhlke LJ, Murray CJL. Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. *The Lancet* 2016;388:1545–1602.


- [87] Winkler TW, Justice AE, Graff M, Barata L, Feitosa MF, Chu S, Czajkowski J, Esko T, Fall T, Kilpeläinen TO, Lu Y, Mägi R, Mihailov E, Pers TH, Rüeger S, Teumer A, Ehret GB, Ferreira T, Heard-Costa NL, Karjalainen J, Lagou V, Mahajan A, Neinast MD, Prokopenko I, Simino J, Teslovich TM, Jansen R, Westra H-J, White CC, Absher D, Ahluwalia TS, Ahmad S, Albrecht E, Alves AC, Bragg-Gresham JL, de Craen AJM, Bis JC, Bonnefond A, Boucher G, Cadby G, Cheng Y-C, Chiang CWK, Delgado G, Demirkan A, Dueker N, Eklund N, Eiriksdottir G, Eriksson J, Feenstra B, Fischer K, Frau F, Galesloot TE, Geller F, Goel A, Gorski M, Grammer TB, Gustafsson S, Haitjema S, Hottenga J-J, Huffman JE, Jackson AU, Jacobs KB, Johansson Å, Kaakinen M, Kleber ME, Lahti J, Leach IM, Lehne B, Liu Y, Lo KS, Lorentzon M, Luan J, Madden PAF, Mangino M, McKnight B, Medina-Gomez C, Monda KL, Montasser ME, Müller G, Müller-Nurasyid M, Nolte IM, Panoutsopoulou K, Pascoe L, Paternoster L, Rayner NW, Renström F, Rizzi F, Rose LM, Ryan KA, Salo P, Sanna S, Scharnagl H, Shi J, Smith AV, Southam L, Stančáková A, Steinthorsdottir V, Strawbridge RJ, Sung YJ, Tachmazidou I, Tanaka T, Thorleifsson G, Trompet S, Pervjakova N, Tyrer JP, Vandenput L, van der Laan SW, van der Velde N, van Setten J, van Vliet-Ostaptchouk JV, Verweij N, Vlachopoulou E, Waite LL, Wang SR, Wang Z, Wild SH, Willenborg C, Wilson JF, Wong A, Yang J, Yengo L, Yerges-Armstrong LM, Yu L, Zhang W, Zhao JH, Andersson EA, Bakker SJL, Baldassarre D, Banasik K, Barcella M, Barlassina C, Bellis C, Benaglio P, Blangero J, Blüher M, Bonnet F, Bonnycastle LL, Boyd HA, Bruinenberg M, Buchman AS, Campbell H, Chen Y-DI, Chines PS, Claudi-Boehm S, Cole J, Collins FS, de Geus EJC, de Groot LCPGM, Dimitriou M, Duan J, Enroth S, Eury E, Farmaki A-E, Forouhi NG, Friedrich N, Gejman PV, Gigante B, Glorioso N, Go AS, Gottesman O, Gräßler J, Grallert H, Grarup N, Gu Y-M, Broer L, Ham AC, Hansen T, Harris TB, Hartman CA, Hassinen M, Hastie N, Hattersley AT, Heath AC, Henders AK, Hernandez D, Hillege H, Holmen O, Hovingh KG, Hui J, Husemoen LL, Hutri-Kähönen N, Hysi PG, Illig T, De Jager PL, Jalilzadeh S, Jørgensen T, Jukema JW, Juonala M, Kanoni S, Karaleftheri M, Khaw KT, Kinnunen L, Kittner SJ, Koenig W, Kolcic I, Kovacs P, Krarup NT, Kratzer W, Krüger J, Kuh D, Kumari M, Kyriakou T, Langenberg C, Lannfelt L, Lanzani C, Lotay V, Launer LJ, Leander K, Lindström J, Linneberg A, Liu Y-P, Lobbens S, Luben R, Lyssenko V, Männistö S, Magnusson PK, McArdle WL, Menni C, Merger S, Milani L, Montgomery GW, Morris AP, Narisu N, Nelis M, Ong KK, Palotie A, Pérusse L, Pichler I, Pilia MG, Pouta A, Rheinberger M, Ribel-Madsen R, Richards M, Rice KM, Rice TK, Rivolta C, Salomaa V, Sanders AR, Sarzynski MA, Scholtens S, Scott RA, Scott WR, Sebert S,

Sengupta S, Sennblad B, Seufferlein T, Silveira A, Slagboom PE, Smit JH, Sparsø TH, Stirrups K, Stolk RP, Stringham HM, Swertz MA, Swift AJ, Syvänen A-C, Tan S-T, Thorand B, Tönjes A, Tremblay A, Tsafantakis E, van der Most PJ, Völker U, Vohl M-C, Vonk JM, Waldenberger M, Walker RW, Wennauer R, Widén E, Willemsen G, Wilsaard T, Wright AF, Zillikens MC, van Dijk SC, van Schoor NM, Asselbergs FW, de Bakker PIW, Beckmann JS, Beilby J, Bennett DA, Bergman RN, Bergmann S, Böger CA, Boehm BO, Boerwinkle E, Boomsma DI, Bornstein SR, Bottinger EP, Bouchard C, Chambers JC, Chanock SJ, Chasman DI, Cucca F, Cusi D, Dedoussis G, Erdmann J, Eriksson JG, Evans DA, de Faire U, Farrall M, Ferrucci L, Ford I, Franke L, Franks PW, Froguel P, Gansevoort RT, Gieger C, Grönberg H, Gudnason V, Gyllenstein U, Hall P, Hamsten A, van der Harst P, Hayward C, Heliövaara M, Hengstenberg C, Hicks AA, Hingorani A, Hofman A, Hu F, Huikuri HV, Hveem K, James AL, Jordan JM, Jula A, Kähönen M, Kajantie E, Kathiresan S, Kiemeny LALM, Kivimäki M, Knekt PB, Koistinen HA, Kooner JS, Koskinen S, Kuusisto J, Maerz W, Martin NG, Laakso M, Lakka TA, Lehtimäki T, Lettre G, Levinson DF, Lind L, Lokki M-L, Mäntyselkä P, Melbye M, Metspalu A, Mitchell BD, Moll FL, Murray JC, Musk AW, Nieminen MS, Njølstad I, Ohlsson C, Oldehinkel AJ, Oostra BA, Palmer LJ, Pankow JS, Pasterkamp G, Pedersen NL, Pedersen O, Penninx BW, Perola M, Peters A, Polašek O, Pramstaller PP, Psaty BM, Qi L, Quertermous T, Raitakari OT, Rankinen T, Rauramaa R, Ridker PM, Rioux JD, Rivadeneira F, Rotter JJ, Rudan I, den Ruijter HM, Saltevo J, Sattar N, Schunkert H, Schwarz PEH, Shuldiner AR, Sinisalo J, Snieder H, Sørensen TIA, Spector TD, Staessen JA, Stefania B, Thorsteinsdottir U, Stumvoll M, Tardif J-C, Tremoli E, Tuomilehto J, Uitterlinden AG, Uusitupa M, Verbeek ALM, Vermeulen SH, Viikari JS, Vitart V, Völzke H, Vollenweider P, Waeber G, Walker M, Wallaschofski H, Wareham NJ, Watkins H, Zeggini E, CHARGE Consortium, DIAGRAM Consortium, GLGC Consortium, Global-BPGen Consortium, ICBP Consortium, MAGIC Consortium, Chakravarti A, Clegg DJ, Cupples LA, Gordon-Larsen P, Jaquish CE, Rao DC, Abecasis GR, Assimes TL, Barroso I, Berndt SI, Boehnke M, Deloukas P, Fox CS, Groop LC, Hunter DJ, Ingelsson E, Kaplan RC, McCarthy MI, Mohlke KL, O'Connell JR, Schlessinger D, Strachan DP, Stefansson K, van Duijn CM, Hirschhorn JN, Lindgren CM, Heid IM, North KE, Borecki IB, Kutalik Z, Loos RJF. The Influence of Age and Sex on Genetic Associations with Adult Body Size and Shape: A Large-Scale Genome-Wide Interaction Study. *PLoS Genet* 2015;11:e1005378.

- [88] Yang C-Y, Chanalaris A, Troeberg L. ADAMTS and ADAM metalloproteinases in osteoarthritis – looking beyond the ‘usual suspects.’ *Osteoarthritis Cartilage* 2017;25:1000–1009.
- [89] Yuan H, Wang W, Chen D, Zhu X, Meng L. Effects of a treatment with Se-rich rice flour high in resistant starch on enteric dysbiosis and chronic inflammation in diabetic ICR mice. *Journal of the Science of Food and Agriculture* 2017;97:2068–2074.
- [90] Zhu Z, Zheng Z, Zhang F, Wu Y, Trzaskowski M, Maier R, Robinson MR, McGrath JJ, Visscher PM, Wray NR, Yang J. Causal associations between risk factors and common diseases inferred from GWAS summary data. *Nature Communications* 2018;9:224.
- [91] Zorina-Lichtenwalter K, Meloto CB, Khoury S, Diatchenko L. Genetic predictors of human chronic pain conditions. *Neuroscience* 2016;338:36–62.
- [92] Zorina-Lichtenwalter K, Parisien M, Diatchenko L. Genetic studies of human neuropathic pain conditions: a review. *PAIN* 2018;159:583.



**Figure 1.** (a) Manhattan plot of CP GWAS showing two significant loci after multiple testing, rs10660361 and rs113313884 mapping to the genes LEMD2 and ADAMTS6 respectively. Annotated are the top SNPs of the discovery GWAS. (b) and (c) LocusTracks of main GWAS. LocusTrack plot for rs113313884 (b) and rs10660361 (c) displaying chromatin state annotation tracks for specific tissues. Red coloured positions in the annotation track indicate open chromatin/active transcription. Tissue tracks in the plots were predefined through DEPICT tissue enrichment analysis top results (see Supplementary Table 3 and 4) of CP.



**Figure 2.** LCV results of CP vs 548 traits displaying genetic correlations. On the X-Axis the likelihood of CP affecting a trait (+1) or the trait affecting CP (-1) is represented. The Y-Axis illustrates the strength of evidence of a causal association (Z score for  $H_0: GCP = 0$ ). The colour indicates the genetic correlation, which ranges from -1 to 1 and indicates whether the trait increases or decreases the risk of CP.

**Table 1.** Phenotypes included from UK Biobank to define chronic pain. If an individual answered yes to having pain in any of the sites below, it was considered a chronic pain case. Only individuals of European descent were included in the analysis.

Phenotype	Male		Female		
	ID	Yes	No	Yes	No
General pain 3+ months	2956	2,002	504	3,421	600
Neck/shoulder pain 3+ months	3404	27,210	14,536	38,857	14,652
Hip pain 3+ months	3414	13,640	4,443	23,567	5,938
Back pain 3+ months	3571	32,963	17,783	39,735	15,427
Stomach/abdominal pain 3+ months	3741	7,338	6,404	11,996	9,046
Knee pain 3+ months	3773	33,253	9,884	37,493	9,154
Headaches 3+ months	3799	10,934	18,797	26,161	25,397
Facial pains 3+ months	4067	980	2,649	2,727	3,243



**Table 2.** Lead SNPs identified in discovery GWAS and significant results (P-value <  $2.06 \times 10^{-6}$ ) of the fastBAT gene-based test. Genomic positions are shown in genome assembly GRCh37 (hg19).

SNP	CHR:POS	Gene closest to SNP	A1/A2	A1 FREQ	OR (s.e.)	P-value
<b>rs10660361</b>	6:33741371	<i>LEMD2</i>	C/CG	0.5756	1.04 ( $6.59 \times 10^{-3}$ )	$2.90 \times 10^{-9}$
<b>rs113313884</b>	5:64629986	<i>ADAMTS6</i>	C/T	0.9723	1.12 (0.0187)	$7.90 \times 10^{-9}$
fastBAT gene-based test results						
Gene Name	CHR	Start	P-value	Top SNP	#SNPs	
<b><i>LEMD2</i></b>	6	33738989	$1.97 \times 10^{-8}$	rs10660361	170	
<b><i>MLN</i></b>	6	33762448	$7.46 \times 10^{-8}$	rs10660361	185	
<b><i>DCAKD</i></b>	17	43100705	$1.01 \times 10^{-6}$	rs2301597	144	
<b><i>NMT1</i></b>	17	43138679	$1.14 \times 10^{-6}$	rs2301597	152	
<b><i>IP6K3</i></b>	6	33689442	$1.75 \times 10^{-6}$	rs10660361	136	

Allele 1 (A1) represents the effect allele (which increases risk for the tested trait) is and Allele 2 (A2) represents the non-effect allele. Beta describes the effect of this SNP with CP and its direction. MAF is the minor allele frequency. OR is the odds ratio and thus, is a ratio between the odds for having the effect allele and the odds of not having the effect allele.